Navigation Links
Heart Defect Is Linked to Some Cases of Migraine Headache

A severe migraine attack can be agonizingly painful and accompanied by extreme light sensitivity and powerful nausea. Medications control some people's headaches, but// for some sufferers no drug completely prevents debilitating attacks.

For such people, hope may come from a new clinical trial, conducted in part at Washington University School of Medicine in St. Louis. The trial offers an unexpected solution — doctors are closing a hole in the heart to try to fix the ache in the head.

About 600 million people around the world, including some 28 million Americans, get migraine headaches. Physicians and researchers suspect a link between migraines and a particular heart defect in some people.

The defect is called a patent foramen ovale or PFO. A remnant of fetal development, a PFO is a hole between the two upper chambers of the heart and is generally smaller than a pencil eraser. In about 25 percent of people, the hole stays partially open after birth, leaving a PFO, a tiny, flap-covered passage between the atria.

“A PFO serves as a strain valve,” explains John M. Lasala, M.D., Ph.D., who oversees the Washington University portion of the migraine/PFO study. “If the pressure gets too high on the right side of the heart, the PFO can open, and blood can travel from the right to the left side. We think something usually cleared out by the lungs is in that blood and can trigger migraines.”

Estimates now hold that PFOs are present in about half of migraine sufferers who experience aura — an arc of zigzag lines in the visual field, numbness of one side of the face, weakness or altered consciousness — and in about a quarter of those who don’t have aura with their migraines.

Early results from a set of ongoing British clinical trials of PFO closure in migraine patients found a 37 percent reduction in migraine frequency and duration. Now the Washington University School of Medicine is one of 13 centers cond ucting a new trial called the ESCAPE trial. (ESCAPE stands for Effect of Septal Closure of Atrial PFO on Events of Migraine with Premere?.) Led by St. Jude Medical in Minnetonka MN, the study aims to close PFOs in 500 migraine patients who haven’t responded well to current medications.

“We don’t believe this will be a cure for all migraines,” says Lasala, medical director of the cardiac catheterization laboratory and professor of medicine. “But even if it’s effective in just 50 percent of migraine patients with PFOs, it could benefit a lot of people.”

The apparatus used to close PFOs in the ESCAPE trial, invented by Dennis W. Wahr, M.D., of St. Jude Medical, delivers a small device to the heart through a vein in the leg. Once in place at the PFO, the tip of the device can be opened like a miniature umbrella with two opposing canopies that press on either side of the wall separating the atria.

“I designed Premere specifically for sealing PFOs — it has a very minimal, open architecture,” Wahr says. “With a PFO, you just have to hold the door shut for a while until it heals, so you don’t need a lot of metal and fabric.”

Sorce-Newswise
SRM
'"/>




Related medicine news :

1. One in Three Heart Attack Patients Have No Chest Pains
2. Epileptic Seizures Can Be Due to Heart Problem
3. Bypass Heart Surgery Performed Without General Anesthesia
4. New CPR Guidelines issued by Heart Association
5. White Cells Count Can Predict Heart Attack Death Risk
6. Vitamins-The answer to Heart Disease?
7. Fight Heart disease and Pain with Meditation
8. Heart disease in the newborn is related to maternal malnutrition
9. New drug to treat Heart Attack and damaged tissue
10. Heart disease threat starts early in life for Diabetics
11. Mechanical Heart
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/24/2017)... ... February 24, 2017 , ... The Radiology Business Management Association will ... at the annual Building Better Radiology Marketing Programs conference, held this year ... Worth, Texas. Nine awards are given out in five categories. They are:, ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... partnership with The Jensie Gran Fondo of Marin. For the second year in ... Thinksport’s broad-spectrum, mineral-based sunscreen. , “We are thrilled to provide our safe, non-toxic ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... a clinician-based audience, will be participating in Rare Disease Day events, hosted by ... In addition, Rare Disease Report, a website, weekly e-newsletter and quarterly publication, will ...
(Date:2/23/2017)... Fair Lawn, NJ (PRWEB) , ... February 23, ... ... specializing in thought leadership , media relations, content marketing, social media ... Vermont. With several clients already in the state and in nearby New Hampshire, ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... an exciting, new, interactive publication where generations converge and explore the world from ... their worldview, Dialog Magazine enables readers to gain understanding, increase empathy, and find ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... , Südkorea, 23. Februar 2017 LG Innotek ... Sterilisationsaufgaben vorgestellt. Die Sterilisationsleistung beträgt das 1,5-fache des 45-mW-Moduls ... Strahlung im Bereich zwischen 200 und 280 nm und eignet ... Bakterien, indem es ihre DNA zerstört. Das Produkt von ... ...
(Date:2/23/2017)... Im Rahmen seiner Schlüsselwachstumsstrategie arbeitet die ... südwestlichen chinesischen Provinz Guizhou, 2017 mit dem Angebot von Anreize ... der Entwicklung einer eingebetteten Hightech-Schlüsselindustrie. Foto - ... ... ...
(Date:2/23/2017)... , February 23, 2017 ... from increasing caseload for varicose veins in their body. ... globe are prompting the adoption of endovenous laser therapy ... global endovenous laser therapy market, published by ... of lifestyle choices and consequences of obesity have collectively ...
Breaking Medicine Technology: